Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s
Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.“Tumor necrosis factor inhibitors (TNFi), including infliximab and adalimumab, are a mainstay of pediatric Crohn’s disease therapy; however, non-response and loss of response are common,” Michael D. Kappelman, MD, MPH,…